Eli Lilly: 2 Billion USD for the Future of Cancer Medicine!
Reading Time: 2 minutes
Eli Lilly (NYSE: LLY) is on the verge of acquiring Kelonia Therapeutics for over 2 billion USD. A remarkable leap, considering that Kelonia has raised less than 60 million USD to date and was last valued at just over 100 million USD in 2022. The deal could come together in the short term and may include additional payments upon reaching certain milestones. Strategically, Lilly would secure access to a promising segment within the approximately 240 billion USD global cancer drug market. The focus is particularly on the treatment of blood cancer multiple...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
